Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
ENDRA Life Sciences Inc
NDRA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$4.74
-0.36
-7.06%
Ult. Agg.: Oct 15, 9:15 AM
$4.80
-0.30
-5.94%
Get Report
Panoramica
Notizie
Previsioni utili
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Privacy Manager
ENDRA Life Sciences Financials
ENDRA Life Sciences (NDRA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ENDRA Life Sciences Q2 EPS $0.06 Beats $(0.84) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.84) by 107.14 percent. This is a 103.51 percent increase over losses of $(1.71) per share
Benzinga Newsdesk
PRO
ENDRA Life Sciences Q1 EPS $(1.09) Beats $(1.14) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.14) by 4.39 percent. This is a 41.4 percent increase over losses of $(1.86) per share from
Benzinga Newsdesk
PRO
ENDRA Life Sciences Q4 EPS $(3.25) Misses $(1.95) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(3.25) per share which missed the analyst consensus estimate of $(1.95) by 66.67 percent. This is a 55.78 percent increase over losses of $(7.35) per share
Benzinga Newsdesk
PRO
ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(2.10) per share which missed the analyst consensus estimate of $(1.95) by 7.69 percent. This is a 77.99 percent increase over losses of $(9.54) per share
Benzinga Newsdesk
PRO
ENDRA Life Sciences Q2 EPS $(1.71) Beats $(2.27) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.71) per share which beat the analyst consensus estimate of $(2.27) by 24.67 percent. This is a 2037.5 percent decrease over losses of $(0.08) per share
Benzinga Newsdesk
PRO
ENDRA Life Sciences Expects Q2 2025 Loss Of ~$1.3M, No Revenue, And ~$2.6M In Total Assets
Recent Financial ResultsBelow is a summary of certain preliminary estimates regarding our financial results for the quarter ended June 30, 2025. This preliminary financial information is based upon our estimates and is
Benzinga Newsdesk
